Use access key #2 to skip to page content.
$21.49 -0.01 (-0.05%)
9/5/2008 4:01 PM

Bristol-Myers Squibb Co. (BMY)

CAPS Rating:
****

The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other health care related products.

View All Commentary (BMY)

Recs

3

Avatar martynanasi (99.39) Submitted: 11/14/06 1:15 PM : Outperform Start Price: $22.62 BMY Score: 5.41

Bristol Myers has had many issues over the last five years. Problems with debt load, production facilites, patent expiration, lack of new drug pipeline etc. At these prices BMY is a good choice for a large pharma. Especially when compared to large rivals such as MRK and PFE. More upsidereward/less risk = larger returns

Report this Post Replies: 0 | Reply

Featured Broker Partners